Aligos Therapeutics, Inc. Financials
Aligos Therapeutics, Inc. (ALGS) reported $3.7M in revenue over the twelve months to Jun 30, 2026, up 19.4% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Development-stage economics dominate Aligos: recurring research spending and operating cash needs far exceed a shrinking revenue base.
Net loss narrowed from$131M to$24M in FY2025, while operating loss did not materially improve. Revenue fell to$2.2M as operating margin worsened to-40.2% , revealing that the earnings improvement did not reflect a stronger core cost-and-revenue engine.
Research and development spending was
FY2025 operating cash flow was
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Aligos Therapeutics, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Aligos Therapeutics, Inc. scores -11.83, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($43.1M) relative to total liabilities ($35.0M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Aligos Therapeutics, Inc. passes 2 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, neither operating efficiency signal passes.
Aligos Therapeutics, Inc. reported a net loss of $24.2M while operations used $82.5M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Aligos Therapeutics, Inc. reported an operating loss of $88.0M against $2.2M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Aligos Therapeutics, Inc. generated $2.2M in revenue in fiscal year 2025. This represents a decrease of 39.5% from the prior year.
Aligos Therapeutics, Inc.'s EBITDA was -$87.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 1.2% from the prior year.
Aligos Therapeutics, Inc. reported -$24.2M in net income in fiscal year 2025. This represents an increase of 81.6% from the prior year.
Aligos Therapeutics, Inc. earned -$2.45 per diluted share (EPS) in fiscal year 2025.
Cash & Balance Sheet
Aligos Therapeutics, Inc. held $18.3M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
Aligos Therapeutics, Inc.'s ROE was -45.2% in fiscal year 2025, measuring profit generated per dollar of shareholder equity.
Not reported for fiscal year 2025.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
Aligos Therapeutics, Inc. invested $69.5M in research and development in fiscal year 2025. This represents a decrease of 1.2% from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
ALGS Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0-100.0% | $2.8M+1574.6% | $169K-77.2% | $741K-23.2% | $965K+210.3% | $311K-48.7% | $606K-51.5% | $1.3M |
| R&D Expenses | $24.1M+3.0% | $23.4M+37.1% | $17.0M-28.8% | $23.9M+71.3% | $14.0M-3.6% | $14.5M-9.5% | $16.0M-4.4% | $16.8M |
| SG&A Expenses | $5.6M-12.3% | $6.4M+29.6% | $4.9M-4.3% | $5.2M-7.0% | $5.6M+10.0% | $5.1M-2.1% | $5.2M+11.6% | $4.6M |
| Operating Income | -$1.9M+93.0% | -$26.9M-23.4% | -$21.8M+23.1% | -$28.4M-52.7% | -$18.6M+3.5% | -$19.2M+6.4% | -$20.6M-2.1% | -$20.1M |
| Interest Expense | $200K+100.0% | $100K-83.3% | $600K+50.0% | $400K0.0% | $400K-50.0% | $800K+166.7% | $300K-40.0% | $500K |
| Income Tax | $2.8M+786.8% | $317K+956.7% | $30K-46.4% | $56K-69.7% | $185K+330.2% | $43K+59.3% | $27K-70.3% | $91K |
| Net Income | -$1.5M+93.5% | -$23.0M-15.9% | -$19.9M+37.0% | -$31.5M-98.8% | -$15.9M-136.8% | $43.1M+152.5% | -$82.2M-326.6% | -$19.3M |
| EPS (Diluted) | -$0.14+93.7% | -$2.21-10.0% | -$2.01+33.9% | -$3.04-98.7% | -$1.53+27.5% | -$2.11+83.9% | -$13.10-326.7% | -$3.07 |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit.
ALGS Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $66.3M+2.7% | $64.6M-27.1% | $88.5M-19.3% | $109.8M-18.5% | $134.7M-10.6% | $150.7M+115.0% | $70.1M-20.7% | $88.4M |
| Current Assets | $62.1M+4.2% | $59.6M-28.0% | $82.9M-19.9% | $103.4M-19.2% | $127.9M-10.7% | $143.2M+130.5% | $62.1M-22.2% | $79.8M |
| Cash & Equivalents | $30.4M+1.3% | $30.0M+63.8% | $18.3M-56.4% | $41.9M+124.8% | $18.7M-74.7% | $73.8M+99.4% | $37.0M+4.7% | $35.3M |
| Accounts Receivable | $27.8M | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $34.4M+5.1% | $32.8M-6.3% | $35.0M-7.8% | $37.9M+15.5% | $32.8M-4.1% | $34.3M-65.4% | $99.1M+158.5% | $38.3M |
| Current Liabilities | $28.3M+21.5% | $23.3M+9.8% | $21.2M-3.4% | $22.0M+8.5% | $20.3M+7.0% | $18.9M-12.8% | $21.7M+3.7% | $21.0M |
| Total Equity | $31.9M+0.3% | $31.8M-40.6% | $53.5M-25.5% | $71.8M-29.5% | $101.9M-12.5% | $116.4M+501.9% | -$29.0M-157.8% | $50.1M |
| Retained Earnings | -$666.7M-0.2% | -$665.2M-3.6% | -$642.2M-3.2% | -$622.3M-5.3% | -$590.8M-2.8% | -$574.9M+7.0% | -$618.0M-15.3% | -$535.9M |
Not reported in any period shown, so not listed: Inventory, Goodwill, Long-Term Debt.
ALGS Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$24.9M-7.9% | -$23.1M-6.4% | -$21.7M+10.7% | -$24.3M-57.0% | -$15.5M+25.9% | -$20.9M-13.6% | -$18.4M+8.4% | -$20.1M |
| Investing Cash Flow | $25.0M-28.4% | $34.9M+1828.4% | -$2.0M-104.2% | $47.7M+221.0% | -$39.4M+10.5% | -$44.1M-320.6% | $20.0M+92.1% | $10.4M |
| Financing Cash Flow | $220K+454.8% | -$62K-150.4% | $123K+332.1% | -$53K+70.1% | -$177K-100.2% | $101.7M+104788.7% | $97K+2525.0% | -$4K |
Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.
ALGS Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Margin | N/A | -951.5% | -12907.7% | -3827.4% | -1924.0% | -6187.5% | -3393.2% | -1610.5% |
| Net Margin | N/A | -814.1% | -11763.9% | -4256.0% | -1643.8% | 13854.7% | -13556.1% | -1540.7% |
| Return on Equity | -4.7%+67.8pp | -72.5%-35.4pp | -37.1%+6.8pp | -43.9%-28.3pp | -15.6%-52.6pp | 37.0% | N/A | -38.4% |
| Return on Assets | -2.3%+33.4pp | -35.7%-13.2pp | -22.5%+6.3pp | -28.7%-16.9pp | -11.8%-40.4pp | 28.6%+145.8pp | -117.2%-95.4pp | -21.8% |
| Current Ratio | 2.19-0.4x | 2.56-1.3x | 3.90-0.8x | 4.70-1.6x | 6.31-1.2x | 7.56+4.7x | 2.86-1.0x | 3.81 |
| Debt-to-Equity | 1.080.0x | 1.03+0.4x | 0.65+0.1x | 0.53+0.2x | 0.320.0x | 0.29 | N/A | 0.77 |
Not reported in any period shown, so not listed: Gross Margin, FCF Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.
Similar Companies
Where Aligos Therapeutics, Inc. Ranks
Frequently Asked Questions
What is Aligos Therapeutics, Inc.'s annual revenue?
Aligos Therapeutics, Inc. (ALGS) reported $2.2M in total revenue for fiscal year 2025. This represents a -39.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Aligos Therapeutics, Inc.'s revenue growing?
Aligos Therapeutics, Inc. (ALGS) revenue declined by 39.5% year-over-year, from $3.6M to $2.2M in fiscal year 2025.
Is Aligos Therapeutics, Inc. profitable?
No, Aligos Therapeutics, Inc. (ALGS) reported a net income of -$24.2M in fiscal year 2025.
What is Aligos Therapeutics, Inc.'s EBITDA?
Aligos Therapeutics, Inc. (ALGS) had EBITDA of -$87.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Aligos Therapeutics, Inc.'s return on equity (ROE)?
Aligos Therapeutics, Inc. (ALGS) has a return on equity of -45.2% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Aligos Therapeutics, Inc.'s operating cash flow?
Aligos Therapeutics, Inc. (ALGS) recorded an outflow of $82.5M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Aligos Therapeutics, Inc.'s total assets?
Aligos Therapeutics, Inc. (ALGS) had $88.5M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Aligos Therapeutics, Inc. spend on research and development?
Aligos Therapeutics, Inc. (ALGS) invested $69.5M in research and development during fiscal year 2025.
What is Aligos Therapeutics, Inc.'s current ratio?
Aligos Therapeutics, Inc. (ALGS) had a current ratio of 3.90 as of fiscal year 2025, which is generally considered healthy.
What is Aligos Therapeutics, Inc.'s debt-to-equity ratio?
Aligos Therapeutics, Inc. (ALGS) had a debt-to-equity ratio of 0.65 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Aligos Therapeutics, Inc.'s return on assets (ROA)?
Aligos Therapeutics, Inc. (ALGS) had a return on assets of -27.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
How does Aligos Therapeutics, Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Aligos Therapeutics, Inc. (ALGS) held $77.8M in cash, cash equivalents and investments, and reported an operating cash outflow of $82.5M over that year. Dividing the one by the other, the reported balance equals about 11 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Aligos Therapeutics, Inc.'s Altman Z-Score?
Aligos Therapeutics, Inc. (ALGS) has an Altman Z-Score of -11.83, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Aligos Therapeutics, Inc.'s Piotroski F-Score?
Aligos Therapeutics, Inc. (ALGS) has a Piotroski F-Score of 2 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Aligos Therapeutics, Inc.'s earnings high quality?
Aligos Therapeutics, Inc. (ALGS) reported a net loss of $24.2M while operations used $82.5M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Aligos Therapeutics, Inc. cover its interest payments?
Aligos Therapeutics, Inc. (ALGS) reported an operating loss of $88.0M against $2.2M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Aligos Therapeutics, Inc.?
Aligos Therapeutics, Inc. (ALGS) scores 45 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.